Fig 1: Levels of cerebral insoluble Aß and mouse ApoJ expression in APP23 transgenic mice over time. a Cerebral accumulation of insoluble Aß40 in 15- and 24-month-old APP23 and wt mice. b Cerebral accumulation of insoluble Aß42 in 15- and 24-month-old APP23 and wt mice. c Mouse ApoJ (m-ApoJ) cerebral expression in 15- and 24-month-old APP23 and wt mice. d Mouse ApoJ (m-ApoJ) levels in the plasma of 15 and 24-month-old APP23 mice. Data are expressed as the mean ± SEM. N = 3–4/group. *p < 0.05; **p < 0.01; *p < 0.001
Fig 2: Subchronic intravenous treatment of APP23 mice with human recombinant ApoJ (h-rApoJ). a Schematic timeline representing the experimental design of the study based on the subchronic administration of APP23 mice with rHDL-rApoJ nanodiscs, free rApoJ or saline. b Immunodetection (anti-h-ApoJ) of treatment samples before being intravenously infused. c Plasmatic levels of h-ApoJ in treated mice 30 min after the last administration detected by ELISA (N = 7/group). d Levels of h-ApoJ in brain homogenates from treated mice detected by ELISA (N = 7/group). e Immunofluorescent detection of h-ApoJ in paraffin-embedded brain sections. **p < 0.01; ***p < 0.001
Supplier Page from Abcam for Mouse Clusterin ELISA Kit (Apolipoprotein J)